

DAFTAR REFERENSI

1. Mims C, Playfair J, Roitt I, et al. Medical Microbiology. 2nd ed. London: Mosby International; 1998: 25-7, 411-9.
2. Brooks GF, Butel JS, Morse SA. Jawetz, Melnick, & Adelberg's medical microbiology. 23rd ed. New York: Lange medical books; 2004 :15-31, 184-186.
3. Todar K. Structure and Function of Bacterial Cells. In: Todar's Online Textbook of Bacteriology [homepage on the internet]. c2009 [updated 2009; cited 2009 June 23]. Available from: http://www.textbookofbacteriology.net/structure_5.html
4. Ryan K J, editor. Sherris medical microbiology. New York: Prentice-Hall International Inc.; 1998.
5. Talaro K, Talaro A. Foundation in microbiology. New York: Wm. C. Brown Publisher; 1996.
6. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. Journal of Antimicrobial Chemotherapy 2003;5:1109-17.
7. Mandell GL, Sande MA. Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In: Goodman LS, Limbird LE, Milinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: Pergamon Press;1996:1057-72.
8. Health Technology Assessment Indonesia. Penggunaan Siprofloksasin di Indonesia [homepage on the internet]. c2005 [updated 2005; cited 2009 June 02]. Available from: <http://www.yanmedik-depket.net/hta/hasil%20kajian.htm>
9. Rahardja THT, Kirana. Obat-obat penting: khasiat, penggunaan dan efek-efek sampingnya. Jakarta: Elex Media Komputindo;2002:148-50.
10. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician 2000 May 1;61(9):2741-8.

11. Science Blog. FDA issues public health advisory on liver toxicity associated with the antibiotic trovan [homepage on the internet]. c2004 [updated 2004; cited 2009 June 23]. Available from:
<http://www.scienceblog.com/community/older/archives/M/1/fda0567.htm>
12. Ambrose PG, Owens RC. New antibiotics in pulmonary and critical care medicine [homepage on the internet]. c2000 [updated 2008 April 04; cited 2000 March 01]. Available from:
<http://www.medscape.com/viewarticle/410872>
13. Hooper DC. Fluoroquinolones [homepage on the internet]. c2009 [updated 2009; cited 2000 June 23]. Available from:
<http://www.utdol.net/patients/content/topic.do?topicKey=~qEUrb6fygy6XYO#1>
14. [Zechiedrich](#) EL, [Cozzarelli](#) N R. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. *Genes & Dev.* 1995;9:2859-69.
15. [Wikler](#) MA, National Committee for Clinical Laboratory Standards, et al. NCCLS M100-S14: Performance standards for antimicrobial susceptibility testing; informational supplement – 14th Edition. Wayne, Pa. : NCCLS. 2004:4-7, 31.
16. Sianipar O, Ariningrum D. Pengaruh volume sampel terhadap pertumbuhan mikroorganisme pada biakan darah. *Berkala Ilmu Kedokteran* 2003;35(3):127-8.
17. Koneman EW et al. Koneman's color atlas and textbook of diagnostic microbiology 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2006. p. 100-1
18. Gunadi D. Pola Kuman Rumah Sakit Husada Juli – Desember 2001 dan Efisiensi Penggunaan Antibiotika. RS Husada [homepage on the Internet].c 2006 [updated 2006 August 28; cited 2009 June 03]. Available from [http://www.husada.co.id/files/Dr.Diana slide A.ppt](http://www.husada.co.id/files/Dr.Diana%20slide%20A.ppt)[Recovered].pdf
19. Garg A, Anupurba S, Garg J, Goyal RK, Sen MR. Bacteriological Profile and Antimicrobial Resistance of Blood Culture Isolates from a University Hospital. *Journal Indian Academy of Clinical Medicine* 2007; 8(2): 139-43

20. Arora U, Devi P. Bacterial profile of blood stream infections and antibiotic resistance pattern of isolates. *J.K. Science* 2007;9(4):186-190.
21. Vila J, Almela M, Jimenez de Anta MT. Laboratory Investigation Of Hospital Outbreak Caused By Two Different Multiresistant *Acinetobacter Calcoaceticus* Subsp. *Anitratus* Strains. *Journal Of Clinical Microbiology* 1989 May;27(5):1086-1089.
22. Grady RW. Systemic quinolone antibiotics in children: a review of the use and safety [abstract]. *Expert Opinion on Drug Safety* 2005 July; 4(4): 623-630.
23. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of *Acinetobacter* spp. in Europe [abstract]. *Clin Microbiol Infect.* 2004 Dec;10(12):1106-7.
24. Casin I, Breuil J, Darchis JP, Guelpa C, Collatz E. Fluoroquinolone-resistant *Salmonella enterica* Typhimurium in humans. *Emerging Infectious Diseases Journal* 2003;9(11).
25. Olsen SJ, DeBess EE, McGivern TE, et al. A Nosocomial Outbreak of Fluoroquinolone-Resistant *Salmonella* Infection. *N Engl J Med* 2001;344(21).
26. Principles of Diagnostic Medical Microbiology. In: Brooks GF, Carroll KC, Butel JS, Morse SA, editors. *Jawetz, Melnick, & Adelberg's Medical Microbiology*, 24th Edition. New York: McGraw-Hill, 2007; p. 699-719.
27. Fluoroquinolone (Oral route, injection route, intravenous route) [homepage on the internet]. c2009 [updated 2009 Mei 4; cited 2009 June 02]. Available from:
<https://ssl.adam.com/content.aspx?productId=47&pid=47&gid=601913&site=welldynerx.adam.com&login=well1815>
28. Health Technology Assessment. Penggunaan Siprofloksasin di Indonesia [homepage on the internet]. c2005 [updated 2005; cited 2009 June 02]. Available from: <http://www.yanmedik-depket.net/hta/hasil%20kajian.htm>
29. Ampel, NM. *Pseudomonas aeruginosa* Bacteremia [homepage on the internet]. c2008 [updated 2008 August 27; cited 2009 June 23]. Available from: <http://infectious-diseases.jwatch.org/cgi/content/full/2008/827/4>

30. Arora U, Devi P. Bacterial profile of blood stream infections and antibiotic resistance pattern of isolates. *J.K. Science* 2007;9(4):186-190.
31. [Algun U](#), [Arisoy A](#), [Gunduz T](#), [Ozbakkaloglu B](#). The resistance of pseudomonas aeruginosa strains to fluoroquinolone group of antibiotics. *Indian J Med Microbiol.* 2004 April-June;22(2):112-4.
32. Nadeem SR, Rina K, Hamimah H and Savithri DP. Pseudomonas aeruginosa: Epidemiology of Bacteremia and Antimicrobial Susceptibility Pattern in a Teaching Hospital in Kuala Lumpur. *Journal of the Medical Centre* 2006;9(1):14-9
33. Umeh O. Klebsiella Infections [homepage on the internet]. c2009 [updated 2008 May 15; cited 2009 June 02]. Available from: <http://emedicine.medscape.com/article/219907>
34. Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 2001;14: 933–51.
35. Harish BN, Menezes GA, Shekatkar S, Parija SC. Extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* from blood culture. *J Med Microbiol* 2007;56:999-1000.
36. Paterson DL, Ko WC, Gottberg AV, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic Therapy for *Klebsiella pneumoniae* Bacteremia: Implications of Production of Extended-Spectrum β -Lactamases. *Clinical Infectious Diseases* 2004;39:31–37.
37. Harish BN, Menezes GA, Shekatkar S, Parija SC. Extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* from blood culture. *J Med Microbiol* 2007;56:999-1000.
38. Al-Zahrani AJ, Akhtar N. Susceptibility Patterns of Extended Spectrum β -Lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated in a teaching hospital. *Pakistan J. Med. Res.* 2005;44(2):64-7.
39. Bartlett JG. Staphylococci, coagulase negative [homepage on the internet]. c2009 [updated 2008 April 04; cited 2009 June 02]. Available from: http://prod.hopkins-abxguide.org/pathogens/bacteria/aerobic_gram-

[positive cocci/staphylococci_coagulase_negative.html?contentInstanceId=255870](#)

40. Rasheed MU, Awole M. Staphylococcus epidermidis : A Commensal Emerging As A Pathogen With Increasing Clinical Significance Especially In Nosocomial Infections. The Internet Journal of Microbiology 2007;3(2).
41. Bartlett JG. Staphylococci, coagulase negative [homepage on the internet]. c2009 [updated 2009 April 04; cited 2009 June 02]. Available from: http://prod.hopkins-abxguide.org/pathogens/bacteria/aerobic_gram-positive_cocci/full_staphylococci_coagulase_negative.html
42. Yuliati. Deteksi gen meca pada methicillin-resistant Staphylococcus aureus (MRSA) dengan teknik PCR[S2 thesis]. Jakarta: Universitas Indonesia.
43. Mayo Foundation for Medical Education and Research. MRSA infection [homepage on the internet]. c2008 [updated 2008 April 05; cited 2009 June 02]. Available from: http://www.riversideonline.com/health_reference/Infectious-Disease/DS00735.cfm
44. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis [serial online] 2003 Nov [cited 2009 June 26]. Available from: <http://www.cdc.gov/ncidod/EID/vol9no11/03-0284.htm>
45. LeBlanc L, Pépin J, Toulouse K, Ouellette M-F, Coulombe M-A, Corriveau M-P, et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis [serial on the Internet]. 2006 Sept [cited 2009 June 26]. Available from: <http://www.cdc.gov/ncidod/EID/vol12no09/06-0397.htm>
46. Health Technology Assessment Indonesia. Sepsis Neonatorum [document on the internet]. 2009 Jan [cited 2009 June 26]. Available from: <http://www.scribd.com/doc/12912905/Final-Koreksi-Draft-Akhir-4-Feb-09>